



*(Incorporated in the Cayman Islands with Limited Liability)*

Stock Code: 0575

1 April 2021

## ANNOUNCEMENT




*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

### OPERATIONS UPDATE CHINESE APPROVAL AND COMMERCIALISATION PROGRESS – FORTACIN™



This announcement is made by Regent Pacific Group Limited (the “**Company**” and collectively with its subsidiaries, the “**Group**”) in compliance with the disclosure requirements under Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**HK Listing Rules**”) and the Inside Information Provisions (as defined under the HK Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).



The directors (the “**Directors**” or the “**Board**”) of the Company refer to the operations update announcement made on 9 February 2021 and are pleased to inform the shareholders of the Company and potential investors of the following update in respect of the Chinese approval and commercialisation progress of Senstend™ (otherwise known as Fortacin™).



As previously announced, following the National Medical Products Administration (“**NMPA**”) approval of Senstend™ for Clinical Trial Approval in China on 5 February 2021, Wanbang Biopharmaceutical Group Co., Ltd. (“**Wanbang Biopharmaceutical**”), the Company’s commercial strategic partner for China and a wholly controlled company of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.,

became obligated to pay the Group US\$3.20 million (or approximately HK\$24.96 million) before deduction of PRC withholding tax, or US\$2.88 million (or approximately HK\$22.46 million) net of PRC withholding tax.

The Directors are pleased to report that this payment was received, in full, on 31 March 2021.

All efforts will continue to be directed towards commencement of the randomised clinical trial, which remains on track to commence in April / May 2021, with an estimated end point of 12 months thereafter. In this respect and as previously advised, Wanbang Biopharmaceutical has appointed a leading contract research organisation to undertake the phase III double blinded multi-centre randomised clinical trial and the Group looks forward to undertaking this next critical step towards commercialisation of Senstend™ in Mainland China.

If the clinical study meets its endpoints and NMPA has granted an import licence for Senstend™, then US\$5 million (or approximately HK\$39 million) before deduction of PRC withholding tax will be payable to the Group from Wanbang Biopharmaceutical. In addition, upon first commercial sale of Senstend™ in China, US\$2 million (or approximately HK\$15.6 million) before deduction of PRC withholding tax shall be payable to the Group from Wanbang Biopharmaceutical. In addition, the Group will generate low to mid-teens royalties of Wanbang Biopharmaceutical's net sales of Senstend™ in China.

The Group will continue to work closely and diligently with its current and prospective commercial partners and will keep shareholders and potential investors informed of any new developments as and when they occur.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

Note: Unless otherwise specified herein, amounts dominated into US\$ have been translated, for the purpose of illustration only, into HK\$ using the exchange rate of US\$1.00 = HK\$7.80.

On Behalf of the Board of  
**Regent Pacific Group Limited**

Jamie Gibson  
*Executive Director*

**Directors of the Company:**

James Mellon (*Chairman*)\*

Jamie Gibson (*Chief Executive Officer*)

David Comba<sup>#</sup>

Julie Oates<sup>#</sup>

Mark Searle<sup>#</sup>

Jayne Sutcliffe\*

\* *Non-Executive Directors*

# *Independent Non-Executive Directors*

Hong Kong, 1 April 2021